MELGESIC 15MG TABLETS

Država: Cipar

Jezik: grčki

Izvor: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

Aktivni sastojci:

MELOXICAM

Dostupno od:

DELORBIS PHARMACEUTICALS LTD (0000009620) 17 ATHINON STREET, ERGATES INDUSTRIAL AREA, LEFKOSIA, 2081, 28629

ATC koda:

M01AC06

INN (International ime):

MELOXICAM

Doziranje:

15MG

Farmaceutski oblik:

TABLETS

Sastav:

MELOXICAM (0071125387) 15MG

Administracija rute:

ORAL USE

Tip recepta:

Εθνική Διαδικασία

Područje terapije:

MELOXICAM

Proizvod sažetak:

Νομικό καθεστώς: Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 10 TABS IN BLISTER(S) (210009501) 10 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 20 TABS IN BLISTER(S) (210009502) 20 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται; PACK WITH 30 TABS IN BLISTER(S) (210009503) 30 TABLET - Εγκεκριμένο - Με Ιατρική Συνταγή που Επαναλαμβάνεται

Uputa o lijeku

COMPARATIVE TABLE ENGLISH VS GREEK PIL
PACKAGE LEAFLET: INFORMATION FOR THE USER
MELGESIC 7,5 MG TABLETS
MELGESIC 15 MG TABLETS
Meloxicam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE
BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs of illness are the same
as
yours.

If you get any side effects, talk to your doctor. This includes any
possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Melgesic is and what it is used for
2.
What you need to know before you take Melgesic
3.
How to take Melgesic
4.
Possible side effects
5.
How to store Melgesic
6.
Contents of the pack and other information
1.
WHAT MELGESIC IS AND WHAT IT IS USED FOR
Melgesic contains the active substance meloxicam. Meloxicam belongs to
a
group of medicines called non-steroidal anti-inflammatory drugs
(NSAIDs)
which are used to reduce inflammation and pain in joints and muscles.
Melgesic tablets are indicated in adults and children aged 16 years
and
ΦΎΛΛΟ ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ: ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ
ΤΟV ΧΡΉΣΤΗ
MELGESIC 7,5 MG ΔΙΣΚΊΑ
MELGESIC 15 MG ΔΙΣΚΊΑ
Μελοξικάμη
ΔΙΑΒΆΣΤΕ ΠΡΟΣΕΚΤΙΚΆ ΟΛΌΚΛΗΡΟ ΤΟ ΦΎΛΛΟ
ΟΔΗΓΙΏΝ ΧΡΉΣΗΣ ΠΡΙΝ
ΑΡΧΊΣΕΤΕ ΝΑ ΠΑΊΡΝΕΤΕ ΑΥΤΌ ΤΟ ΦΆΡΜΑΚΟ,
ΔΙΌΤΙ ΠΕΡΙΈΧΕΙ ΣΗΜΑΝΤΙΚΈΣ
ΠΛΗΡΟΦΟΡΊΕΣ ΓΙΑ ΣΑΣ.

Φυλάξτε αυτό το φύλλο οδηγιών χρήσης.
Ίσως χρειαστεί να το
διαβάσετε ξανά.

Εάν έχετε περαιτέρω απορίες, ρωτήστε
το γιατρό ή το φαρμακοποιό
σας.

Η συνταγή για αυτό το φάρμακο
χορηγήθηκε αποκλειστικ�

Svojstava lijeka

1.
NAME OF THE MEDICINAL PRODUCT
Melgesic 7.5 mg Tablets
Melgesic 15 mg Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 7.5 mg meloxicam.
Excipient(s) with known effect: each tablet contains 71.30 mg of
lactose
Each tablet contains 15 mg meloxicam.
Excipient(s) with known effect: each tablet contains 142.60 mg of
lactose
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets
For 7.5mg strength:
Light yellow, round, flat tablet, 8mm diameter, cross-scored on one
side.
For 15mg strength:
Light yellow, round, concave tablet, 10mm diameter, scored on one
side.
4.
CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
- Short-term symptomatic treatment of exacerbations of osteoarthrosis.
- Long-term symptomatic treatment of rheumatoid arthritis or
ankylosing spondylitis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Oral use
The total daily amount should be taken as a single dose, with water or
another liquid, during a meal.
Undesirable effects may be minimised by using the lowest effective
dose for the shortest duration
necessary to control symptoms (see section 4.4). The patient's need
for symptomatic relief and
response to therapy should be re-evaluated periodically, especially in
patients with osteoarthritis.
1
SUMMARY OF PRODUCT CHARACTERISTICS
- Exacerbations of osteoarthrosis: 7.5 mg/day.
If necessary, in the absence of improvement, the dose may be increased
to 15 mg/day.
- Rheumatoid arthritis, ankylosing spondylitis: 15 mg/day.
(see also section 'Special populations' below)
According to the therapeutic response, the dose may be reduced to 7.5
mg/day.
DO NOT EXCEED THE DOSE OF 15 MG/DAY.
Special populations
_Elderly patients and patients with increased risks for adverse
reaction (see section 5.2):_
The recommended dose for long term treatment of rheumatoid arthritis
and ankylosing spondylitis in
elderly patients is 7.5 mg per day. Patients with increased risks for
adverse reactions should start
treatment with 7.5 mg per day (see section 4.4).
_Renal impairment (see sectio